TrialThe Lancet. Oncology2017

Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial.

Corneel Coens et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.